Scarica l'app Stockscreener
50.66
5.22%
-2.6104
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$53.27
Aprire:
$52.852
Volume 24 ore:
5.65M
Relative Volume:
0.69
Capitalizzazione di mercato:
$20.10B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-6.2188
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+3.48%
1M Prestazione:
-0.37%
6M Prestazione:
+102.28%
1 anno Prestazione:
+98.08%
Intervallo 1D:
$49.99
$53.05
Intervallo di 1 settimana:
$47.78
$59.48
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
50.65 | 21.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
454.54 | 113.78B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
719.23 | 75.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.75 | 50.55B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.29 | 38.99B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
316.80 | 32.69B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally - The Motley Fool
Moderna stock (US60770K1034): Ranked #1 on TIME's 2026 Most Impactful Companies - AD HOC NEWS
Still ‘many steps to do’ in creating a hantavirus vaccine, experts say - Global News
Stock market today: S&P 500, Dow futures fall as Trump rejects 'totally unacceptable' Iran peace proposal—Micron Technologies, Moderna in focus - MSN
Moderna stock (US60770K1034): Gains 0.74% to $53.27 on May 12 - AD HOC NEWS
Arbutus Biopharma Q1 revenue surges on Moderna settlement - TradingView
Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit - Stock Titan
Moderna Is a Money-Losing Vaccine Maker. It’s Also the Ultimate Stock Hedge. - Barron's
Money-Losing Moderna Is a Pandemic Hedge. What to Do With the Stock Now. - Barron's
Moderna (MRNA) Shares Skyrocket, What You Need To Know - Yahoo Finance
Moderna Recognized by TIME as One of the World's Most Impactful Companies - ACCESS Newswire
Why TIME ranked Moderna the world's most impactful company in 2026 - Stock Titan
Transcript : Moderna, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 11 - marketscreener.com
Biotech Stocks Sway Amid Hantavirus Cruise Scare - Investing News Network
Moderna (MRNA) Targets August FDA Decision as mRNA Flu Vaccine Clears Phase 3 Efficacy Bar - AlphaStreet
Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell (NASDAQ:MRNA) - Seeking Alpha
Moderna's Revenues See Strong International Momentum in Q1 Earnings - TradingView
Moderna Inc. stock (US60770K1034): Jumps 8% on hantavirus hype, Q1 earnings beat - AD HOC NEWS
MODERNA : Jefferies reiterates its Neutral rating - marketscreener.com
Hantavirus outbreak: these 3 stocks are poised to rip higher - Invezz
Hantavirus Fears Fuel Moderna Rally: Is This a Real Catalyst or Just Sentiment? - NAI500
5 Insightful Analyst Questions From Moderna’s Q1 Earnings Call - Yahoo Finance
Moderna reports Q1 loss, stock jumps on strong international sales - MSN
Nvidia, Lumentum, Intel, Micron, Qualcomm, Tesla, Moderna, Circle Internet, and More Movers - Barron's
Key facts: Moderna mRNA hantavirus vaccines; stock up, $74 target - TradingView
Moderna stock pops as investors zero in on hantavirus work following the deadly cruise ship outlook - Business Insider
Moderna Stock Is Surging on Hantavirus Threats. Its Chart Offers a Harsh Dose of Reality. - Barchart.com
Moderna Stock Loses Steam. Hantavirus Trade Fizzles as Officials Dismiss Pandemic Risk. - Barron's
Moderna (MRNA) Develops Hantavirus Vaccine Amid Low Pandemic Thr - GuruFocus
Moderna Shares Have Rallied. Why the Stock Could Climb Another 30%. - Barron's
Moderna (MRNA) Shares Rise Amid Hantavirus Treatment Evaluation - GuruFocus
Moderna stock (US60770K1034): Shares rally 12% on hantavirus vaccine research - AD HOC NEWS
Moderna shares jump as it reveals it has been researching vaccines against hantaviruses - Yahoo Finance
Moderna’s stock has rallied on hantavirus research that is ‘early-stage’ in nature - MarketWatch
Moderna (MRNA) Stock Rises Amid Hantavirus Outbreak Concerns - GuruFocus
Best Biotech Stocks To Follow NowMay 11th - MarketBeat
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? - 24/7 Wall St.
Moderna shares extend gains as hantavirus vaccine work draws attention - Proactive financial news
Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging. - Investopedia
Moderna stock soars as hantavirus fears spark outbreak trade - TradingView
Moderna stock (US60770K1034): Q1 earnings beat on revenue, EPS miss sparks gains - AD HOC NEWS
Moderna stock extends gains on hantavirus research - Yahoo Finance
MRNA Stock Jumps As Earnings Beat Fuels Pipeline Hype - timothysykes.com
Stocks to Watch: Moderna, Intel, MidCap Financial -- WSJ - Moomoo
Moderna shares jump 8% after U.S. national tests positive for hantavirus - Investing.com
Premarket Winners: Moderna (MRNA), Intel (INTC), and Micron (MU) Rally on Monday - Blockonomi
Today’s Market Movers: Moderna, Intel, and Micron Lead Premarket Gains - CoinCentral
Moderna (MRNA) Stock Jumps After Hantavirus Outbreak Sparks Biotech Rally - CoinCentral
Moderna stock surges on hantavirus vaccine, flu trial data - Yahoo Finance
S&P 500 Futures Steady In Premarket Trading; Everpure, Moderna Lead - Moomoo
Moderna jumps on word it is working on a hantavirus vaccine - MSN
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):